Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Status:	Archived
Conditions:	Brain Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	Any
Updated:	7/1/2011

A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Thalidomide may stop the growth of glioblastoma multiforme by blocking blood flow to the
tumor. Isotretinoin may help cells that are involved in the body's immune response to work
better. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. It is not yet known which temozolomide-containing regimen is more effective
in treating glioblastoma multiforme.

PURPOSE: This randomized phase II trial is studying eight different temozolomide-containing
regimens to compare how well they work in treating patients who have undergone radiation
therapy for glioblastoma multiforme.

OBJECTIVES:

- Compare the efficacy of adjuvant temozolomide alone or in combination with thalidomide
and/or isotretinoin and/or celecoxib, in terms of 6-month progression-free survival, in
patients who have undergone radiotherapy for supratentorial glioblastoma multiforme.

- Compare the toxicity of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 8
treatment arms.

- Arm I: Patients receive oral temozolomide once daily on days 1-7 and 15-21.

- Arm II: Patients receive temozolomide as in arm I and oral thalidomide once daily on
days 1-28.

- Arm III: Patients receive temozolomide as in arm I and oral isotretinoin twice daily on
days 1-21.

- Arm IV: Patients receive temozolomide as in arm I and oral celecoxib twice daily on
days 1-28.

- Arm V: Patients receive temozolomide as in arm I, thalidomide as in arm II, and
isotretinoin as in arm III.

- Arm VI: Patients receive temozolomide as in arm I, thalidomide as in arm II, and
celecoxib as in arm IV.

- Arm VII: Patients receive temozolomide as in arm I, isotretinoin as in arm III, and
celecoxib as in arm IV.

- Arm VIII: Patients receive temozolomide as in arm I, thalidomide as in arm II,
isotretinoin as in arm III, and celecoxib as in arm IV.

In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease
progression or unacceptable toxicity. Patient may receive additional courses of therapy at
the discretion of the treating physician.

After completion of study treatment, patients are followed for at least 30 days and then
every 3 months thereafter.

PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.

We found this trial at

sites

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

Ft. Smith, Arkansas 72903

from

Ft. Smith, AR